Dr. Jag Khalsa, with about 50 years of experience in drug research, serves as the Chief of the Medical Consequences Branch, National Institute on Drug Abuse, NIH, DHHS; is responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others).
Prior to joining NIDA in 1987, he served for ~10 yrs as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at FDA.
has published in pharmacology, toxicology, epidemiology and medical journals.
He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases.
He also serves on numerous Federal and NIH level committees including the HHS Viral Hepatitis Implementation Group (VHIG), National Commission on Digestive Diseases and its two sub-committees (Liver Research, Diabetes Research), Federal Task Force on TB, NIH Steering Committee on Centers for AIDS Research, and Human Microbiome Workgroup.
has received distinguished service awards from the FDA
and NIH Directors, Society of Neuro-Immune-Pharmacology
(SNIP), Life Time Achievement Awards from SNIP
and International Conference on Molecular Medicine (India) and MIT
, India; a commendation from the US Congress
, Awards of Merit from the International Society of Addiction Medicine
(ISAM), the President of the American Society of Addiction Medicine
(ASAM), and a Certificate of Appreciation from the Office of Assistant Secretary for Health (Drs. Howard Koh and Ron Valdiserri), DHHS
He has a PhD in neuro-psycho-pharmacology, a Master's degree in herbal pharmacology, post-doctoral training in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International.
Jag Khalsa, MS, PhD